NLRP3 and metabolic dysfunction-associated steatohepatitis: Given this promising potential of Nlrp3 inhibition as a treatment for NASH, we undertook a systematic investigation of the effects of both genetic deletion and pharmacologic inhibition of Nlrp3 on experimental steatohepatitis.